Recent Updates
Recently added Catalysts
INSM Positive Sentiment Score: 70/100

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...

Key Takeaway: Insmed Incorporated has announced inducement grants under NASDAQ Listing Rule 5635(c)(4) to 24 new employees. The awards include options to purchase 143,650 shares of common stock at $28.06 per share, with a 10-year term and a gradual vesting schedule. This initiative reflects Insmed's commitment to expanding its workforce as it focuses on transforming the lives of patients with serious and rare diseases through innovative therapies. The company continues to advance its pipeline and research efforts in various therapeutic areas.

Market Sentiment Analysis

POSITIVE FACTORS

  • Insmed granted inducement awards to 24 new employees, indicating growth and recruitment.
  • The options provided have a long vesting period, encouraging employee retention.
  • Insmed is advancing a robust pipeline of therapies for serious unmet needs.

Full Press Release Details

BRIDGEWATER, N.J. , March 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM ), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 24 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
In connection with the commencement of their employment, the employees received options on March 1, 2024 to purchase an aggregate 143,650 shares of Insmed common stock at an exercise price of $28.06 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.
The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey , with additional offices and research locations throughout the United States , Europe , and Japan . Visit www.insmed.com to learn more.
Bryan Dunn Executive Director, Investor Relations Insmed (646) 812-4030 [email protected]
Eleanor Barisser Associate Director, Investor Relations Insmed (718) 594-5332 [email protected]
Mandy Fahey Executive Director, Corporate Communications Insmed (732) 718-3621 [email protected]
SOURCE Insmed Incorporated

21 %

Frequently Asked Questions

What company granted inducement awards to new employees?

Insmed Incorporated granted inducement awards to 24 new employees.

What was the total number of shares granted to new employees?

Employees received options for a total of 143,650 shares of common stock.

What is the exercise price for the stock options given?

The exercise price for the stock options is $28.06 per share.

What is the vesting schedule for the stock options?

The options have a four-year vesting schedule with specific vesting percentages.

What type of diseases does Insmed focus on?

Insmed focuses on serious and rare diseases, including chronic lung disease.

Last updated: Mar 5, 2024